A relook at preventive therapy for tuberculosis in children

Indian Journal of Pediatrics

Volumn 78, Issue 2, 2011, Pages 205-210

  Singh, Varinder ^a   Patra, Soumya ^a  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

Chemoprophylaxis; Childhood tuberculosis; INH therapy. Childhood contacts; Preventive therapy

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHEMOPROPHYLAXIS; CHILD HEALTH; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EARLY DIAGNOSIS; HEPATITIS; HUMAN; IMMUNOCOMPROMISED PATIENT; LATENT PERIOD; LIVER FAILURE; LIVER TOXICITY; LUNG TUBERCULOSIS; MORBIDITY; MORTALITY; NAUSEA; PREVENTIVE MEDICINE; RECOMMENDED DRUG DOSE; REINFECTION; SIDE EFFECT; THORAX RADIOGRAPHY; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; BREAST FEEDING; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT, NEWBORN; ISONIAZID; PREGNANCY; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 79953867811     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12098-010-0257-0     Document Type: Article

References (46)

1. WHO report (2009) Global tuberculosis control. [http://www.who. int/tb/publications/global-report/2009/key-points/en/index.html]
2. Kabra SK, Lodha R, Seth V. Some current concepts on childhood tuberculosis. Indian J Med Res. 2004;120:387-97. (Pubitemid 39504474)
3. Brent AJ, Anderson ST, Kampmann B. Childhood tuberculosis: Out of sight, out of mind? Trans R Soc Trop Med Hyg. 2007;102:217-8.
4. Donald PR. Childhood tuberculosis: Out of control? Curr Opin Pulm Med. 2002;8:178-82. (Pubitemid 34408997)
5. Morrison J, Pai M, Philip J, Hopewell C. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: A systematic review and meta-analysis. Lancet Infect Dis. 2008;8:259-68.
6. The Official Statement of American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 1994;149:1359-74.
7. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc. 1975;50:90-106.
8. Van Geuns HA, Meijer J, Styblo K. Results of contact examination in Rotterdam, 1967-1969. Bull Int Union Tuberc. 1975;50:107-21.
9. Lienhardt CK, Fielding K. Risk factors for tuberculosis infection in sub-Saharan Africa: A contact study in the Gambia. Am J Respir Crit Care Med. 2003;168:448-55. (Pubitemid 37046874)
10. Becerra MC, Pachao-Torreblana IF. Expanding tuberculosis case detection by screening household contacts. Public Health Rep. 2005;120:271-7. (Pubitemid 40631537)
11. Rieder HL. Interventions for tuberculosis control and elimination. Paris: International Union Against Tuberculosis and Lung Disease; 2002.
12. Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bull Int Union Tuberc. 1975;50:90-106.
13. Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162:2033-8. (Pubitemid 32051659)
14. Kenyon TA, Creek T, Laserson K, et al. Risk factors for transmission of Mycobacterium tuberculosis from HIV-infected tuberculosis patients, Botswana. Int J Tuberc Lung Dis. 2002;6:843-50. (Pubitemid 35190696)
15. Leinhardt C, Sillah J, Fielding K, et al. Risk factors for tuberculosis infection in children in contact with infectious tuberculosis cases in The Gambia, West Africa. Pediatr. 2003;111:e608-14.
16. Tuberculosis Research Centre, Indian Council of Medical Research, Chennai, India Additional risk of developing TB for household members with a TB case at home at intake: A 15-year study. Int J Tuberc Lung Dis 11(3):282-288
17. Beyers N, Gie RP, Schaaf HS, et al. A prospective evaluation of children under the age of 5 years living in the same household as adults with recently diagnosed pulmonary tuberculosis. Int J Tuberc Lung Dis. 1997;1:38-43. (Pubitemid 127509684)
18. Topley JM, Maher D, Nyong'onya Mbewe L. Transmission of tuberculosis to contacts of sputum positive adults in Malawi. Arch Dis Child. 1996;74:140-5.
19. Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood pulmonary tuberculosis: A critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8:392-402. (Pubitemid 38624845)
20. Jagota P, Suryanarayana HV, Chadha VK. Childhood tuberculosis today. J Intern Med India. 1997;8:121-4. (Pubitemid 27320012)
21. Hsu KHK. Thirty years after isoniazid: Its impact on tuberculosis in children and adolescents. JAMA. 1984;251:1283-5. (Pubitemid 14195205)
22. Apers L, Robert C, Nachega JB. Prophylaxis with antituberculous drugs in special situations. In: Schaaf SH, Zumla AH editors. Tuberculosis a Comprehensive Clinical Reference. 1ed Elsevier 2009;780-85.
23. World Health Organization. Tuberculosis in children. In: Treatment of tuberculosis: Guidelines for National Programmes. 3rd ed. WHO/ CDS/TB/2003.313. Geneva, Switzerland: WHO, 2003: 61-66.
24. Enarson DA, Rieder HL, Arnadottir T, Trébucq A. Treating the disease. In: Management of tuberculosis: A guide for low income countries. 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000: 11-24.
25. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: The effects of chemotherapy. Tubercle. 1976;57:275-99.
26. Marais BJ, Gie RP, Schaaf HS, et al. The clinical epidemiology of childhood pulmonary tuberculosis: A critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8:278-85. (Pubitemid 38624864)
27. Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics. 2004;114:1175-201.
28. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons (Cochrane Review). The Cochrane Library, Issue 2. Chichester: Wiley; 2004.
29. Hsu KH. Isoniazid in the prevention and treatment of tuberculosis. A 20-year study of the effectiveness in children. JAMA. 1974;229:528-33.
30. Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis. 1962;85:490-521.
31. Donald PR, Schaaf HS. Old and new drugs for the treatment of tuberculosis in children. Paediatr Respir Rev. 2007;8:134-41. (Pubitemid 46893988)
32. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: Results of an 11-year randomized study. Clin Infect Dis. 2007;45:715-22. (Pubitemid 47378885)
33. van Zyl S, Marais Ben J, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis. 2006;10(1):13-8. (Pubitemid 43266271)
34. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/ British Medical Research Council. A double-blind placebocontrolled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis. 1992;145:36-41.
35. Menzies D, Long R, Trajman A, Dion MJ, Yang J, Al Jahdali A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection. A randomized trial. Ann Intern Med. 2008;149:689-97.
36. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49:1-51.
37. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci. 2008;335:126-36. (Pubitemid 351253409)
38. Livengood JR, Sigler TG, Foster LR, Jeannette GB, Snider DE. Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure. JAMA. 1985;253:2847-9. (Pubitemid 15033081)
39. Sterling TR, Hackman J, Horsburgh CR, Chaisson RE, Wang YC, Quinn E, et al. Tuberculosis Trials Consortium. Design of Tuberculosis Trials Consortium Study 26: Once-weekly rifapentine plus isoniazid (INH) for 3 months vs. daily INH for 9 months for the treatment of latent TB infection. Presented at the 4th World Congress on Tuberculosis, Washington, DC, 3-5 June 2002: Abstract 143.
40. Gao XF, Wang L, Liu GJ, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: A metaanalysis. Int J Tuberc Lung Dis. 2006;10:1080-90. (Pubitemid 44519344)
41. Prasad BNBM. A Study on comparative efficacy of anti tubercular chemoprophylaxis with 2 different regimen. Lung India. 2006;23:64-9.
42. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: An international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA. 2000;283:1445-50. (Pubitemid 30151823)
43. Centers for Disease Control and Prevention (CDC). Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:735-9.
44. World Health Organization. Guidelines for the programmatic management of drugresistant tuberculosis. WHO/HTM/TB/2006. Geneva, Switzerland: WHO, 2006.
45. Fraser A, Paul M, Attamna A, Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: Systematic review. Int J Tuberc Lung Dis. 2006;10:19-23. (Pubitemid 43266272)
46. Stop TB Partnership Childhood TB Subgroup. Chapter 4: Childhood contact screening and management [Official Statement. Guidance for National Tuberculosis Programmes on the management of tuberculosis in children. Chapter 4 in the series]. Int J Tuberc Lung Dis 11(1):12-15.